c peptide

Summary

Summary: A 31-amino acid peptide which connects the A and B chains of proinsulin. The exact composition of the peptide is species dependent. In beta cells proinsulin is enzymatically converted to insulin with the liberation of the C-peptide. An immunoassay has been developed for assessing pancreatic beta cell secretory function in diabetic patients in whom circulating insulin antibodies and exogenous insulin interfere with insulin immunoassay.

Top Publications

  1. ncbi Effects of C-peptide on forearm blood flow and brachial artery dilatation in patients with type 1 diabetes mellitus
    E Fernqvist-Forbes
    Department of Surgical Sciences, Section of Clinical Physiology, Karolinska Hospital, Stockholm, Sweden
    Acta Physiol Scand 172:159-65. 2001
  2. ncbi Acute inhibition of lipolysis does not affect postprandial suppression of endogenous glucose production
    Peter E Carey
    Dept of Medicine, The Medical School, Framlington Place, Newcastle upon Tyne NE2 4HH, UK
    Am J Physiol Endocrinol Metab 289:E941-7. 2005
  3. ncbi C-peptide improves adenosine-induced myocardial vasodilation in type 1 diabetes patients
    Bo Lennart Johansson
    Department of Surgical Sciences, Division of Clinical Physiology N1 05, Karolinska Institutet, Karolinska Hospital, SE 171 76 Stockholm, Sweden
    Am J Physiol Endocrinol Metab 286:E14-9. 2004
  4. ncbi Human proinsulin C-peptide reduces high glucose-induced proliferation and NF-kappaB activation in vascular smooth muscle cells
    Vincenza Cifarelli
    Division of Immunogenetics, Department of Pediatrics, University of Pittsburgh, School of Medicine, Pittsburgh, PA 15213, USA
    Atherosclerosis 201:248-57. 2008
  5. ncbi Five-year follow-up after clinical islet transplantation
    Edmond A Ryan
    Department of Medicine, Clinical Islet Transplant Program, 2000 College Plaza, 8215 112th St, Edmonton, Alberta, Canada T6G 2C8
    Diabetes 54:2060-9. 2005
  6. ncbi International trial of the Edmonton protocol for islet transplantation
    A M James Shapiro
    Clinical Islet Transplant Program, University of Alberta, Edmonton, AB, Canada
    N Engl J Med 355:1318-30. 2006
  7. ncbi Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial
    Michael W Steffes
    Department of Laboratory Medicine and Pathology, University of Minnesota Medical School, Minneapolis, Minnesota 55455, USA
    Diabetes Care 26:832-6. 2003
  8. ncbi Successful islet transplantation: continued insulin reserve provides long-term glycemic control
    Edmond A Ryan
    Department of Medicine, Clinical Islet Transplant Program, University of Alberta and Capital Health Authority, 2000 College Plaza, 8215 112th Street, Edmonton, Alberta, Canada T6G 2C8
    Diabetes 51:2148-57. 2002
  9. ncbi Mechanisms of the age-associated deterioration in glucose tolerance: contribution of alterations in insulin secretion, action, and clearance
    Rita Basu
    Endocrine Research Unit, Mayo Medical School, Rochester, Minnesota, USA
    Diabetes 52:1738-48. 2003
  10. ncbi Hyper-insulinaemia and cancer, meta-analyses of epidemiological studies
    Paola Pisani
    Cancer Epidemiology Unit, Richard Doll Building, The Oxford University, Old Road Campus, Roosevelt Drive, Headington, Oxford
    Arch Physiol Biochem 114:63-70. 2008

Detail Information

Publications328 found, 100 shown here

  1. ncbi Effects of C-peptide on forearm blood flow and brachial artery dilatation in patients with type 1 diabetes mellitus
    E Fernqvist-Forbes
    Department of Surgical Sciences, Section of Clinical Physiology, Karolinska Hospital, Stockholm, Sweden
    Acta Physiol Scand 172:159-65. 2001
    ..Our results demonstrate that physiological concentrations of C-peptide increase resting forearm blood flow, brachial artery diameter and left ventricular systolic function in patients with type 1 diabetes...
  2. ncbi Acute inhibition of lipolysis does not affect postprandial suppression of endogenous glucose production
    Peter E Carey
    Dept of Medicine, The Medical School, Framlington Place, Newcastle upon Tyne NE2 4HH, UK
    Am J Physiol Endocrinol Metab 289:E941-7. 2005
    ..Acute pharmacological sequestration of fatty acids in triglyceride stores improves postprandial glucose homeostasis without effect on the immediate postprandial suppression of EGP...
  3. ncbi C-peptide improves adenosine-induced myocardial vasodilation in type 1 diabetes patients
    Bo Lennart Johansson
    Department of Surgical Sciences, Division of Clinical Physiology N1 05, Karolinska Institutet, Karolinska Hospital, SE 171 76 Stockholm, Sweden
    Am J Physiol Endocrinol Metab 286:E14-9. 2004
    ..05) and stroke volume (+7%, P < 0.05). It is concluded that short-term C-peptide infusion in physiological amounts increases the hyperemic MBF and left-ventricular function in type 1 diabetic patients...
  4. ncbi Human proinsulin C-peptide reduces high glucose-induced proliferation and NF-kappaB activation in vascular smooth muscle cells
    Vincenza Cifarelli
    Division of Immunogenetics, Department of Pediatrics, University of Pittsburgh, School of Medicine, Pittsburgh, PA 15213, USA
    Atherosclerosis 201:248-57. 2008
    ..In patients with T1D, physiological C-peptide levels may exert beneficial effects on the vasculature that, under high glucose conditions, is subject to progressive dysfunction...
  5. ncbi Five-year follow-up after clinical islet transplantation
    Edmond A Ryan
    Department of Medicine, Clinical Islet Transplant Program, 2000 College Plaza, 8215 112th St, Edmonton, Alberta, Canada T6G 2C8
    Diabetes 54:2060-9. 2005
    ..The results, though promising, still point to the need for further progress in the availability of transplantable islets, improving islet engraftment, preserving islet function, and reducing toxic immunosuppression...
  6. ncbi International trial of the Edmonton protocol for islet transplantation
    A M James Shapiro
    Clinical Islet Transplant Program, University of Alberta, Edmonton, AB, Canada
    N Engl J Med 355:1318-30. 2006
    ..We conducted an international, multicenter trial to explore the feasibility and reproducibility of islet transplantation with the use of a single common protocol (the Edmonton protocol)...
  7. ncbi Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial
    Michael W Steffes
    Department of Laboratory Medicine and Pathology, University of Minnesota Medical School, Minneapolis, Minnesota 55455, USA
    Diabetes Care 26:832-6. 2003
    ..Also, continuing C-peptide (insulin) secretion is important in avoiding hypoglycemia (the major complication of intensive diabetic therapy)...
  8. ncbi Successful islet transplantation: continued insulin reserve provides long-term glycemic control
    Edmond A Ryan
    Department of Medicine, Clinical Islet Transplant Program, University of Alberta and Capital Health Authority, 2000 College Plaza, 8215 112th Street, Edmonton, Alberta, Canada T6G 2C8
    Diabetes 51:2148-57. 2002
    ..Islet transplantation is a reasonable option in those with severe problems with glycemic lability or hypoglycemia...
  9. ncbi Mechanisms of the age-associated deterioration in glucose tolerance: contribution of alterations in insulin secretion, action, and clearance
    Rita Basu
    Endocrine Research Unit, Mayo Medical School, Rochester, Minnesota, USA
    Diabetes 52:1738-48. 2003
    ....
  10. ncbi Hyper-insulinaemia and cancer, meta-analyses of epidemiological studies
    Paola Pisani
    Cancer Epidemiology Unit, Richard Doll Building, The Oxford University, Old Road Campus, Roosevelt Drive, Headington, Oxford
    Arch Physiol Biochem 114:63-70. 2008
    ..The hypothesis that high circulating levels of insulin could be the underlying factor increasing cancer risk has been proposed. Epidemiological studies on markers of hyper-insulinaemia and cancer are reviewed and summarized...
  11. ncbi Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes
    Bart Keymeulen
    Academic Hospital and Diabetes Research Center, Brussels Free University VUB, Brussels
    N Engl J Med 352:2598-608. 2005
    ..To provide proof of this therapeutic principle at the metabolic level, we initiated a phase 2 placebo-controlled trial with a humanized antibody, an aglycosylated human IgG1 antibody directed against CD3 (ChAglyCD3)...
  12. ncbi Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study
    Mette Zander
    Department of Medical Physiology, Panum Institute, University of Copenhagen, Copenhagen, Denmark
    Lancet 359:824-30. 2002
    ..Glucagon-like peptide 1 (GLP-1) has been proposed as a treatment for type 2 diabetes. We have investigated the long-term effects of continuous administration of this peptide hormone in a 6-week pilot study...
  13. ncbi Clinical outcomes and insulin secretion after islet transplantation with the Edmonton protocol
    E A Ryan
    Department of Medicine, Surgical Medical Research Institute, University of Alberta, Edmonton, Canada
    Diabetes 50:710-9. 2001
    ..An elevation of creatinine appears to be a contraindication to this immunosuppressive regimen. For the subjects who had labile type 1 diabetes that was difficult to control, the risk-to-benefit ratio is in favor of islet transplantation...
  14. ncbi Patients with neuroglycopenia after gastric bypass surgery have exaggerated incretin and insulin secretory responses to a mixed meal
    A B Goldfine
    Joslin Diabetes Center, One Joslin Place, Boston, Massachusetts 02215, USA
    J Clin Endocrinol Metab 92:4678-85. 2007
    ..The etiology of the syndrome and metabolic characteristics remain incompletely understood. Recent studies suggest that levels of incretin hormones are increased after GB and may promote excessive beta-cell function and/or growth...
  15. ncbi Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes
    P V Højberg
    Department of Endocrinology, Hvidovre Hospital, Kettegaards Alle 30, DK 2650 Hvidovre, Denmark
    Diabetologia 52:199-207. 2009
    ..The aim of the present study was to investigate whether 4 weeks of near-normalisation of the blood glucose level could improve insulin responses to GIP and GLP-1 in patients with type 2 diabetes...
  16. ncbi C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop, 21-22 October 2001
    Jerry P Palmer
    Department of Medicine, University of Washington, and DVA Puget Sound Health Care System, Seattle, Washington 98108, USA
    Diabetes 53:250-64. 2004
    ..The development of therapies for addressing this important unmet clinical need will be facilitated by trials that are carefully designed with beta-cell function as determined by C-peptide measurement as the primary efficacy outcome...
  17. ncbi Assessing insulin secretion by modeling in multiple-meal tests: role of potentiation
    Andrea Mari
    C N R National Research Council Institute of Systems Science and Biomedical Engineering, Padua, Italy
    Diabetes 51:S221-6. 2002
    ..Use of the model in patients with type 2 diabetes retrieves known defects in insulin secretion but also uncovers new facets of beta-cell dysfunction...
  18. ncbi Identification and characterization of metabolically benign obesity in humans
    Norbert Stefan
    Department of Internal Medicine IV, University of Tubingen, D 72076 Tubingen, Germany
    Arch Intern Med 168:1609-16. 2008
    ..Conversely, even in obesity, a metabolically benign fat distribution phenotype may exist...
  19. ncbi Expression of adiponectin receptor mRNA in human skeletal muscle cells is related to in vivo parameters of glucose and lipid metabolism
    Harald Staiger
    Department of Internal Medicine IV, Medical Clinic Tübingen, Otfried Muller Str 10, D 72076 Tubingen, Germany
    Diabetes 53:2195-201. 2004
    ..AdipoR1, but not AdipoR2, expression correlated with insulin secretion. The molecular nature of this link between muscle and beta-cells needs to be further clarified...
  20. ncbi C-peptide is a bioactive peptide
    J Wahren
    Department of Molecular Medicine and Surgery, Karolinska Hospital, 171 76, Stockholm, Sweden
    Diabetologia 50:503-9. 2007
  21. pmc Too much glucagon, too little insulin: time course of pancreatic islet dysfunction in new-onset type 1 diabetes
    Rebecca J Brown
    National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland, USA
    Diabetes Care 31:1403-4. 2008
    ..To determine the time course of changes in glucagon and insulin secretion in children with recently diagnosed type 1 diabetes...
  22. ncbi Directed differentiation of human embryonic stem cells into the pancreatic endocrine lineage
    Blaine W Phillips
    ES Cell International Pte, Ltd, Singapore 138667
    Stem Cells Dev 16:561-78. 2007
    ..When transplanted into severe combined immunodeficiency (SCID) mice, differentiated cell populations retain their endocrine identity and synthesize insulin...
  23. ncbi Insulin and C-peptide secretion and kinetics in humans: direct and model-based measurements during OGTT
    A Tura
    Institute of Systems Science and Biomedical Engineering, Italian National Research Council, 35127 Padua, Italy
    Am J Physiol Endocrinol Metab 281:E966-74. 2001
    ..3, r(2) = 0.93), whereas estimation of hepatic insulin extraction and insulin clearance needs further investigation for improvement...
  24. ncbi The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects
    Lise L Kjems
    Department of Endocrinology, Hvidovre Hospital, University of Copenhagen, Denmark
    Diabetes 52:380-6. 2003
    ..Nevertheless, the results also indicate that the dose-response relation between beta-cell responsiveness to glucose and GLP-1 is severely impaired in patients with type 2 diabetes...
  25. ncbi C-Peptide replacement therapy and sensory nerve function in type 1 diabetic neuropathy
    Karin Ekberg
    Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden
    Diabetes Care 30:71-6. 2007
    ..The present study was undertaken to examine whether C-peptide administration to patients with type 1 diabetes and peripheral neuropathy improves sensory nerve function...
  26. ncbi Prognostic factors for the course of beta cell function in autoimmune diabetes
    C Torn
    Department of Medicine, University Hospital, 221 85 Lund, Sweden
    J Clin Endocrinol Metab 85:4619-23. 2000
    ..Other factors such as age, gender, body mass index, levels of ICA, IA-2A or IAA had no prognostic importance...
  27. ncbi Latent autoimmune diabetes in adults: definition, prevalence, beta-cell function, and treatment
    Gunnar Stenström
    Department of Medicine, Kungsbacka Hospital, Goteborg, Sweden
    Diabetes 54:S68-72. 2005
    ..In agreement with proved impaired beta-cell function at diagnosis of diabetes, insulin is the treatment of choice...
  28. ncbi Dimorphic histopathology of long-standing childhood-onset diabetes
    R Gianani
    Barbara Davis Center for Childhood Diabetes, University of Colorado Denver, 1775 Aurora Court, Aurora, CO 80055, USA
    Diabetologia 53:690-8. 2010
    ..The aim of this study was to characterise the pancreases of childhood-onset diabetes in order to define the pathological basis of this heterogeneity...
  29. ncbi Generation of insulin-producing cells from PDX-1 gene-modified human mesenchymal stem cells
    Yanhua Li
    Department of Stem Cells and Regenerative Medicine, Beijing Institute of Transfusion Medicine, Beijing, China
    J Cell Physiol 211:36-44. 2007
    ..These findings validate the hMSCs model system as a potential basis for enrichment of human beta cells or their precursors, and a possible source for cell replacement therapy in diabetes...
  30. ncbi High risk of sensitization after failed islet transplantation
    P M Campbell
    Department of Medicine, and Histocompatability Laboratory, University of Alberta, Capital Health, Edmonton, Alberta, Canada
    Am J Transplant 7:2311-7. 2007
    ..This may negatively impact the ability of these individuals to undergo further islet, pancreas or kidney transplantation and should be discussed upfront during evaluation of candidates for islet transplantation...
  31. ncbi A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes
    Kevan C Herold
    Associate Professor of Medicine, Columbia University, PH10 105, 630 W 168th St, New York, NY 10032, USA
    Diabetes 54:1763-9. 2005
    ....
  32. ncbi Stimulation of endothelial nitric oxide synthase by proinsulin C-peptide
    Thomas Wallerath
    Department of Pharmacology, Johannes Gutenberg University, Mainz, Germany
    Nitric Oxide 9:95-102. 2003
    ..We suggest that this effect may contribute to the increase in skin and muscle blood flow previously demonstrated in human in vivo...
  33. ncbi Metabolic factors affecting residual beta cell function assessed by C-peptide secretion in patients with newly diagnosed type 1 diabetes
    A Picardi
    Department of Endocrinology and Diabetes, University Campus Bio Medico, Via E Longoni 83, 00155 Rome, Italy
    Horm Metab Res 38:668-72. 2006
    ..How metabolic parameters at diagnosis influence residual C-peptide secretion is not well established...
  34. ncbi Visualization of early engraftment in clinical islet transplantation by positron-emission tomography
    Torsten Eich
    N Engl J Med 356:2754-5. 2007
  35. ncbi Human C-peptide antagonises high glucose-induced endothelial dysfunction through the nuclear factor-kappaB pathway
    P Luppi
    Division of Immunogenetics, Department of Pediatrics, Rangos Research Center, Children s Hospital of Pittsburgh, 3460 Fifth Avenue, Pittsburgh, PA 15213, USA
    Diabetologia 51:1534-43. 2008
    ....
  36. ncbi Natural history of beta-cell function in type 1 diabetes
    Nicole A Sherry
    Naomie Berrie Diabetes Center and Department of Pediatrics, College of Physicians and Surgeons, Columbia University, 1150 St Nicholas Ave, New York, New York 10032, USA
    Diabetes 54:S32-9. 2005
    ..Understanding the modifiers and predictors of beta-cell function would allow targeting immunological approaches to those individuals most likely to benefit from therapy...
  37. ncbi Limited capacity of human adult islets expanded in vitro to redifferentiate into insulin-producing beta-cells
    Ayse G Kayali
    Department of Pediatrics, USCD Whittier Institute, University of California San Diego, 9894 Genesee Avenue, La Jolla, CA 92037 3495, USA
    Diabetes 56:703-8. 2007
    ..Attempts at cell differentiation after expansion by both methods failed to consistently recover a beta-cell phenotype. Redifferentiation of beta-cells after expansion is still a challenge in need of a solution...
  38. ncbi The case for intravenous arginine stimulation in lieu of mixed-meal tolerance tests as outcome measure for intervention studies in recent-onset type 1 diabetes
    Carla Greenbaum
    Benaroya Research Institute, Diabetes Clinical Research, Seattle, Washington 98101, USA
    Diabetes Care 27:1202-4. 2004
  39. ncbi C-peptide inhibits leukocyte-endothelium interaction in the microcirculation during acute endothelial dysfunction
    R Scalia
    Department of Physiology, Jefferson Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA
    FASEB J 14:2357-64. 2000
    ....
  40. ncbi Proinsulin C-peptide abrogates type-1 diabetes-induced increase of renal endothelial nitric oxide synthase in rats
    Akihiro Kamikawa
    Department of Biomedical Sciences, Graduate School of Veterinary Medicine, Hokkaido University, Sapporo, Japan
    Diabetes Metab Res Rev 24:331-8. 2008
    ..The aim of this study was to elucidate the effect of C-peptide and insulin as a reference on the eNOS expression in the early phase of type 1 diabetic rat kidney...
  41. ncbi Indices of insulin action, disposal, and secretion derived from fasting samples and clamps in normal glucose-tolerant black and white children
    Gabriel I Uwaifo
    Unit on Growth and Obesity, Developmental Endocrinology Branch, National Institutes of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland 20892, USA
    Diabetes Care 25:2081-7. 2002
    ..To validate fasting indices of insulin sensitivity and secretion in a diverse pediatric population against gold standard estimates from euglycemic and hyperglycemic clamps...
  42. pmc Trends of earlier and later responses of C-peptide to oral glucose challenges with progression to type 1 diabetes in diabetes prevention trial-type 1 participants
    Jay M Sosenko
    Division of Endocrinology, University of Miami, Miami, Florida, USA
    Diabetes Care 33:620-5. 2010
    ..001); peak C-peptide levels were less predictive (P < 0.05). CONCLUSIONS A decreased early C-peptide response to oral glucose and an increased later response occur at least 2 years before the diagnosis of type 1 diabetes...
  43. pmc C-peptide in the natural history of type 1 diabetes
    Jerry P Palmer
    Department of Medicine, Veterans Affairs Puget Sound Health Care System and University of Washington, Seattle, WA, USA
    Diabetes Metab Res Rev 25:325-8. 2009
    ....
  44. ncbi Residual C-peptide secretion and endothelial function in patients with Type II diabetes
    Daniela Manzella
    Department of Geriatric Medicine and Metabolic Diseases, IV Internal Medicine, Piazza Miraglia 2, I 80138 Napoli, Italy
    Clin Sci (Lond) 105:113-8. 2003
    ..In conclusion, our study demonstrated that patients with Type II diabetes with good residual C-peptide secretion are better protected from endothelial dysfunction that those with poor C-peptide secretion...
  45. ncbi Random C-peptide in the classification of diabetes
    B Berger
    Department of Medicine KSS Skövde, Sweden
    Scand J Clin Lab Invest 60:687-93. 2000
    ..To clarify whether random C-peptide is a valuable test in the classification of diabetes...
  46. ncbi Natural history of kidney graft survival, hypertrophy, and vascular function in end-stage renal disease type 1 diabetic kidney-transplanted patients: beneficial impact of pancreas and successful islet cotransplantation
    Paolo Fiorina
    Department of Medicine, San Raffaele Scientific Institute, Via Olgettina 60, 20132 Milan, Italy
    Diabetes Care 28:1303-10. 2005
    ..Our aim was to evaluate survival, hypertrophy, and vascular function of the kidney graft in end-stage renal disease (ESRD) type 1 diabetic patients after transplant...
  47. ncbi Unordered structured of proinsulin C-peptide in aqueous solution and in the presence of lipid vesicles
    M Henriksson
    Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden
    Cell Mol Life Sci 57:337-42. 2000
    ..In conclusion, C-peptide is unlikely to elicit physiological effects through stable conformation-dependent interactions with lipid membranes...
  48. ncbi Comparison of the effects of amitriptyline and flunarizine on weight gain and serum leptin, C peptide and insulin levels when used as migraine preventive treatment
    M S Berilgen
    Firat University School of Medicine, Department of Neurology, Elazig, Turkey
    Cephalalgia 25:1048-53. 2005
    ..A result from this study indicates that AMT and flunarizine may cause leptin resistance possibly by different mechanisms and thereby result in increase in serum leptin levels and BMI...
  49. ncbi [Continuous enteral nutrition versus single bolus: effects on urine C peptide and nitrogen balance]
    Alejandro Sanz París
    Servicio de Endocrinologia y Nutricion, Hospital Miguel Servet, Zaragoza, Spain
    Med Clin (Barc) 124:613-5. 2005
    ..Our study was designed to assess the impact on nitrogen and glucose metabolism when it is administered either as discontinuous or as continuous infusion...
  50. ncbi Insulin, C-peptide, hyperglycemia, and central nervous system complications in diabetes
    Anders A F Sima
    Department of Pathology, Gordon H Scott Hall of Basic Medical Sciences, Wayne State University, 540 East Canfield Avenue, Detroit, MI 48201, USA
    Eur J Pharmacol 490:187-97. 2004
    ..Here, we will review the clinical and experimental data supporting this conceptual division of diabetic CNS complications and discuss the underlying metabolic, molecular, and functional aberrations...
  51. pmc Mixed-meal tolerance test versus glucagon stimulation test for the assessment of beta-cell function in therapeutic trials in type 1 diabetes
    Carla J Greenbaum
    TrialNet Publications, The Biostatistics Center, Rockville, Maryland, USA
    Diabetes Care 31:1966-71. 2008
    ..The Type 1 Diabetes TrialNet Research Group and the European C-peptide Trial (ECPT) Study Group conducted parallel randomized studies to compare the sensitivity, reproducibility, and tolerability of these procedures...
  52. ncbi Robust improvements in fasting and prandial measures of beta-cell function with vildagliptin in drug-naïve patients: analysis of pooled vildagliptin monotherapy database
    R E Pratley
    University of Vermont College of Medicine, Burlington, VT, USA
    Diabetes Obes Metab 10:931-8. 2008
    ..To assess the effects of 24-week treatment with vildagliptin on measures of beta-cell function in a broad spectrum of drug-naïve patients with type 2 diabetes (T2DM)...
  53. ncbi Insulin dose-response curves for stimulation of splanchnic glucose uptake and suppression of endogenous glucose production differ in nondiabetic humans and are abnormal in people with type 2 diabetes
    Rita Basu
    Division of Endocrinology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Diabetes 53:2042-50. 2004
    ..Taken together, these data also suggest that agents that enhance SGU in diabetic patients (e.g. glucokinase activators) are likely to improve glucose tolerance...
  54. ncbi Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus
    Julio C Voltarelli
    Department of Clinical Medicine, School of Medicine of Ribeirao Preto, University of Sao Paulo, Ribeirao Preto, Brazil
    JAMA 297:1568-76. 2007
    ..Previous animal and clinical studies suggest that moderate immunosuppression in newly diagnosed type 1 DM can prevent further loss of insulin production and can reduce insulin needs...
  55. pmc Type 1 diabetic neuropathy and C-peptide
    Anders A F Sima
    Department of Pathology, Wayne State University, Detroit, Michigan 48201, USA
    Exp Diabesity Res 5:65-77. 2004
    ..Large-scale food and drug administration (FDA)-approved clinical trials are necessary to make this natural substance available to the globally increasing type 1 diabetic population...
  56. ncbi Integration of local and central laboratory functions in a worldwide multicentre study: Experience from the Hyperglycemia and Adverse Pregnancy Outcome (HAPO) Study
    G Selby Nesbitt
    Department of Clinical Biochemistry, Royal Victoria Hospital, Belfast BT12 6BA, UK
    Clin Trials 3:397-407. 2006
    ..Local misclassification of participants at the thresholds can introduce recruitment bias and adversely affect the integrity of study findings...
  57. ncbi Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes
    O Klein
    Profil Institut für Stoffwechselforschung GmbH, Neuss, Germany
    Diabetes Obes Metab 9:290-9. 2007
    ..This study compared the time-action profiles of the novel albumin-bound basal insulin analogue NN344 with those of insulin detemir and insulin glargine in individuals with type 2 diabetes...
  58. ncbi Effects of age and sex on postprandial glucose metabolism: differences in glucose turnover, insulin secretion, insulin action, and hepatic insulin extraction
    Rita Basu
    Mayo Clinic College of Medicine, 200 1st St SW, Rm 5 194 Joseph, Rochester, MN 55905, USA
    Diabetes 55:2001-14. 2006
    ....
  59. ncbi Cellular and physiological effects of C-peptide
    Claire E Hills
    Department of Infection, Immunity and Inflammation, University of Leicester School of Medicine, Leicester LE1 7RH, UK
    Clin Sci (Lond) 116:565-74. 2009
    ..Therefore a picture of Type 1 diabetes as a dual-hormone-deficiency disease is developing, suggesting that the replacement of C-peptide alongside insulin should be considered in its management...
  60. ncbi Molecular effects of proinsulin C-peptide
    Jan Johansson
    Department of Medical Biochemistry and Biophysics, Karolinska Institutet, SE 171 77 Stockholm, Sweden
    Biochem Biophys Res Commun 295:1035-40. 2002
    ..Combined, the available observations show that C-peptide is biologically active and suggest a molecular model for its physiological effects...
  61. ncbi Transcription factor 7-like 2-gene polymorphism is related to fasting C peptide in latent autoimmune diabetes in adults (LADA)
    Barbara Szepietowska
    Section of Endocrinology, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT, USA
    Acta Diabetol 47:83-6. 2010
    ..Fasting C peptide level was measured by ELISA...
  62. ncbi Proinsulin c-peptide exerts beneficial effects in endotoxic shock in mice
    Michael G Vish
    Division of Critical Care Medicine, Cincinnati Children s Hospital Medical Center, University of Cincinnati College of Medicine, OH, USA
    Crit Care Med 35:1348-55. 2007
    ..This study was designed to investigate the biological effects of c-peptide during endotoxemia...
  63. pmc C-peptide prevents hippocampal apoptosis in type 1 diabetes
    Zhen Guo Li
    Department of Pathology, Morris J Hood Jr Comprehensive Diabetes Center, Wayne State University School of Medicine, Detroit, Michigan 48201, USA
    Int J Exp Diabetes Res 3:241-5. 2002
    ..Our data suggest that type 1 diabetes causes a duration-dependent programmed cell death of the hippocampus, which is partially prevented by C-peptide...
  64. ncbi Amelioration of sensory nerve dysfunction by C-Peptide in patients with type 1 diabetes
    Karin Ekberg
    Department of Surgical Sciences, Section of Clinical Physiology, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden
    Diabetes 52:536-41. 2003
    ..In conclusion, C-peptide administered for 3 months as replacement therapy to patients with early signs of diabetic neuropathy ameliorates nerve dysfunction...
  65. ncbi Oral glucose tolerance test minimal model indexes of beta-cell function and insulin sensitivity
    E Breda
    Department of Electronics and Informatics, University of Padova, Italy
    Diabetes 50:150-8. 2001
    ....
  66. ncbi Exendin 4 up-regulates expression of PDX 1 and hastens differentiation and maturation of human fetal pancreatic cells
    Jamileh Movassat
    Whittier Institute and Department of Pediatrics, University of California, San Diego, La Jolla, California 92037, USA
    J Clin Endocrinol Metab 87:4775-81. 2002
    ..It also accelerates the functional maturation of fetal beta-cells as evidenced by their glucose-stimulated insulin secretion...
  67. ncbi Oral insulin administration and residual beta-cell function in recent-onset type 1 diabetes: a multicentre randomised controlled trial. Diabète Insuline Orale group
    L Chaillous
    Centres Hospitaliers Universitaires de Nantes, France
    Lancet 356:545-9. 2000
    ..We investigated whether oral administration of recombinant human insulin could protect residual beta-cell function in recent-onset type 1 diabetes...
  68. ncbi Mechanisms of endothelial dysfunction with development of type 1 diabetes mellitus: role of insulin and C-peptide
    Irving G Joshua
    Department of Physiology and Biophysics, School of Medicine, University of Louisville, Louisville, Kentucky 40292, USA
    J Cell Biochem 96:1149-56. 2005
    ..These results suggest a synergistic action between insulin and C-peptide that facilitates increase NO availability and may suggest new clinical treatment modalities for type-1 diabetes mellitus...
  69. ncbi Role of C-peptide in human physiology
    J Wahren
    Department of Surgical Sciences, Section of Clinical Physiology, Karolinska Hospital, SE 171 76 Stockholm, Sweden
    Am J Physiol Endocrinol Metab 278:E759-68. 2000
    ..The possibility exists that C-peptide replacement, together with insulin administration, may prevent the development or retard the progression of long-term complications in type 1 diabetes...
  70. ncbi C-peptide: much more than a byproduct of insulin biosynthesis
    Ruy G Marques
    Department of General Surgery, Rio de Janeiro State University, Rio de Janeiro, Brazil
    Pancreas 29:231-8. 2004
    ..The aim of this paper is to present an up-to-date review of C-peptide, focusing on its role in insulin biosynthesis and in the classification of diabetes mellitus, as well as its potential clinical applications...
  71. ncbi Microencapsulated pancreatic islet allografts into nonimmunosuppressed patients with type 1 diabetes: first two cases
    Riccardo Calafiore
    Department of Internal Medicine, University of Perugia, Via E dal Pozzo, 06126 Perugia, Italy
    Diabetes Care 29:137-8. 2006
  72. ncbi Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone
    Y Miyazaki
    University of Texas Health Science Center and Texas Diabetes Institute, San Antonio 78284-7886, USA
    Diabetes Care 24:710-9. 2001
    ..CONCLUSIONS: These results suggest that pioglitazone therapy in type 2 diabetic patients decreases lasting and postprandial plasma glucose levels by improving hepatic and peripheral (muscle) tissue sensitivity to insulin...
  73. ncbi Ligand-independent activation of peroxisome proliferator-activated receptor-gamma by insulin and C-peptide in kidney proximal tubular cells: dependent on phosphatidylinositol 3-kinase activity
    Nawal M Al-Rasheed
    Department of Cell Physiology and Pharmacology, University of Leicester, Leicester LE1 9HN, United Kingdom
    J Biol Chem 279:49747-54. 2004
    ..These results support a new and potentially important physiological role for C-peptide in regulation of PPARgamma-related cell functions...
  74. ncbi Elevated free fatty acids impair glucose metabolism in women: decreased stimulation of muscle glucose uptake and suppression of splanchnic glucose production during combined hyperinsulinemia and hyperglycemia
    Pankaj Shah
    Endocrine Research Unit, Mayo Clinic, Rochester, Minnesota 55905, USA
    Diabetes 52:38-42. 2003
    ....
  75. ncbi Insulin secretion in type 1 diabetes
    Chynna Steele
    Department of Medicine, Division of Endocrinology, and the Naomi Berrie Diabetes Center, College of Physicians and Surgeons, Columbia University, New York, New York, USA
    Diabetes 53:426-33. 2004
    ....
  76. pmc C-peptide and central nervous system complications in diabetes
    Zhen Guo Li
    Department of Pathology, Wayne State University School of Medicine, Detroit, Michigan 48201, USA
    Exp Diabesity Res 5:79-90. 2004
    ..These studies provide a basis for administration of C-peptide as a potentially effective therapy for type 1 diabetes...
  77. ncbi C-peptide stimulates ERK1/2 and JNK MAP kinases via activation of protein kinase C in human renal tubular cells
    Z Zhong
    Section of Clinical Physiology, Department of Surgical Sciences, Karolinska Institute, Stockholm, Sweden
    Diabetologia 48:187-97. 2005
    ..This study examines the intracellular signalling pathways activated by C-peptide in human renal tubular cells...
  78. ncbi Live encapsulated porcine islets from a type 1 diabetic patient 9.5 yr after xenotransplantation
    Robert B Elliott
    Living Cell Technologies, Aukland, New Zealand
    Xenotransplantation 14:157-61. 2007
    ..The long-term viability and function of transplanted encapsulated neonatal porcine islets was examined in a diabetic patient...
  79. ncbi Preservation of C-peptide secretion in subjects at high risk of developing type 1 diabetes mellitus--a new surrogate measure of non-progression?
    Desmond Schatz
    Department of Pediatrics, University of Florida, Gainesville, 32610, USA
    Pediatr Diabetes 5:72-9. 2004
    ..However, preservation of C-peptide production in the prediabetic period appears to indicate non-progression to clinical disease and may serve as a new surrogate for determining response to preventative efforts...
  80. ncbi C-peptide induces chemotaxis of human CD4-positive cells: involvement of pertussis toxin-sensitive G-proteins and phosphoinositide 3-kinase
    Daniel Walcher
    Department of Internal Medicine II Cardiology, University of Ulm, Germany
    Diabetes 53:1664-70. 2004
    ..Thus, C-peptide might deposit in the arterial intima in diabetic patients during early atherogenesis and subsequently attract CD4(+) cells to migrate into the vessel wall...
  81. ncbi Molecular alterations underlie nodal and paranodal degeneration in type 1 diabetic neuropathy and are prevented by C-peptide
    Anders A F Sima
    Wayne State University, Department of Pathology, 540 E Canfield Avenue, Detroit, MI 48201, USA
    Diabetes 53:1556-63. 2004
    ..These data describe for the first time the progressive molecular aberrations underlying nodal and paranodal degenerative changes in type 1 diabetic neuropathy and demonstrate that they are preventable by insulinomimetic C-peptide...
  82. pmc Molecular and cellular effects of C-peptide--new perspectives on an old peptide
    John Wahren
    Department of Surgical Sciences, Section of Clinical Physiology, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden
    Exp Diabesity Res 5:15-23. 2004
    ..Clinical evidence suggests that replacement of C-peptide, together with regular insulin therapy, may be beneficial in patients with type 1 diabetes and serve to retard or prevent the development of long-term complications...
  83. ncbi Laparoscopic approach for human islet transplantation into a defined liver segment in type-1 diabetic patients
    Babak Movahedi
    Department of Surgery, Vrije Universiteit Brussel, Laarbeeklaan 101, 1090, Brussels, Belgium
    Transpl Int 16:186-90. 2003
    ..We conclude that this laparoscopic procedure is a feasible, convenient, and safe alternative method of islet transplantation. Moreover, it allows multiple deliveries of islets into the same liver segment...
  84. ncbi C-peptide stimulates Na+, K+-ATPase via activation of ERK1/2 MAP kinases in human renal tubular cells
    Z Zhong
    Section of Clinical Physiology, Department of Surgical Sciences, Karolinska Institutet, 17177 Stockholm, Sweden
    Cell Mol Life Sci 61:2782-90. 2004
    ..In conclusion, C-peptide stimulates sodium pump activity via ERK1/2-induced phosphorylation of Thr residues on the alpha subunit of Na(+), K(+)-ATPase...
  85. ncbi International comparison of C-peptide measurements
    Hsiao Mei Wiedmeyer
    Department of Pathology and Anatomical Sciences, University of Missouri Columbia School of Medicine, Columbia, MO 65212, USA
    Clin Chem 53:784-7. 2007
    ..We assessed the comparability of C-peptide results obtained with different methods and by different laboratories and determined whether C-peptide results could be harmonized by normalization with a WHO reference reagent or with plasma...
  86. ncbi Reduced insulinotropic effect of gastric inhibitory polypeptide in first-degree relatives of patients with type 2 diabetes
    J J Meier
    Medizinische Klinik, , Knappschafts-Krankenhaus, Bochum (Langendreer, Germany
    Diabetes 50:2497-504. 2001
    ..In conclusion, a reduced insulinotropic activity of GIP is typical for a substantial subgroup of normoglycemic first-degree relatives of patients with type 2 diabetes, pointing to an early, possibly genetic defect...
  87. ncbi Meal-stimulated glucagon release is associated with postprandial blood glucose level and does not interfere with glycemic control in children and adolescents with new-onset type 1 diabetes
    Sven Pörksen
    Department of Pediatrics, Forskerparken, Glostrup University Hospital, DK 2600 Glostrup, Denmark
    J Clin Endocrinol Metab 92:2910-6. 2007
    ..The role of glucagon in hyperglycemia in type 1 diabetes is unresolved, and in vitro studies suggest that increasing blood glucose might stimulate glucagon secretion...
  88. ncbi Evidence that processes other than gluconeogenesis may influence the ratio of deuterium on the fifth and third carbons of glucose: implications for the use of 2H2O to measure gluconeogenesis in humans
    Gerlies Bock
    Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Department of Medicine, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Diabetes 57:50-5. 2008
    ..The current studies determined whether C3 and C5 glucose enrichment is influenced by processes other than gluconeogenesis...
  89. ncbi C-peptide induces a concentration-dependent dilation of skeletal muscle arterioles only in presence of insulin
    M E Jensen
    Department of Physiology, New York Medical College, Valhalla, New York 10595, USA
    Am J Physiol 276:H1223-8. 1999
    ..Furthermore, the effects of insulin appear to be specific for C-peptide and are not the result of a general enhancement of endothelium-dependent or endothelium-independent dilation...
  90. ncbi Insulin sensitivity during oral glucose tolerance test and its relations to parameters of glucose metabolism and endothelial function in type 2 diabetic subjects under metformin and thiazolidinedione
    A Kautzky-Willer
    Department of Internal Medicine III, Medical University of Vienna, Austria
    Diabetes Obes Metab 8:561-7. 2006
    ....
  91. ncbi Incretin effect potentiates beta-cell responsivity to glucose as well as to its rate of change: OGTT and matched intravenous study
    Marco Campioni
    Dept of Information Engineering, Via Gradenigo 6a, 35131 Padua, Italy
    Am J Physiol Endocrinol Metab 292:E54-60. 2007
    ....
  92. ncbi Effects of C-peptide on renal function at the early stage of experimental diabetes
    M Sjoquist
    Department of Physiology, Biomedicum, Uppsala University, Sweden
    Kidney Int 54:758-64. 1998
    ..This investigation was initiated to elucidate and amplify these findings with respect to protein leakage, hyperfiltration and renal functional reserve in diabetic rats...
  93. ncbi Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo
    L Heinemann
    Department of Metabolic Diseases and Nutrition, the World Health Organization Collaborating Centre for Diabetes, Heinrich Heine University, Dusseldorf, Germany
    Diabetes Care 23:644-9. 2000
    ..To study the pharmacodynamic properties of the subcutaneously injected long-acting insulin analog HOE901 (30 microg/ml zinc) in comparison with those of NPH insulin and placebo...
  94. ncbi Influence of family history of diabetes on incidence and prevalence of latent autoimmune diabetes of the adult: results from the Nord-Trøndelag Health Study
    Sofia Carlsson
    Division of Epidemiology, Stockholm Centre of Public Health and Department of Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden
    Diabetes Care 30:3040-5. 2007
    ..The aim of this study was to investigate the association between family history of diabetes (FHD) and prevalence and incidence of latent autoimmune diabetes of the adult (LADA), type 1 diabetes, and type 2 diabetes...
  95. ncbi Effects of free fatty acid elevation on postabsorptive endogenous glucose production and gluconeogenesis in humans
    M Roden
    Department of Internal Medicine III, University of Vienna Medical School, Austria
    Diabetes 49:701-7. 2000
    ..05 vs. glycerol: 64+/-4%). In conclusion, high plasma FFA concentrations increase the percent contribution of GNG to EGP and may contribute to increased rates of GNG in patients with type 2 diabetes...
  96. ncbi C-peptide exerts beneficial effects on myocardial blood flow and function in patients with type 1 diabetes
    Alexander Hansen
    Section of Cardiology, Department of Medicine, Karolinska Hospital, Stockholm, Sweden
    Diabetes 51:3077-82. 2002
    ..3 +/- 0.4 to 5.3 +/- 0.9 (P < 0.05). The results demonstrate that type 1 diabetic patients have impaired myocardial function and perfusion in the basal state that can be improved by short-term replacement of C-peptide...
  97. ncbi GAD treatment and insulin secretion in recent-onset type 1 diabetes
    Johnny Ludvigsson
    Department of Clinical and Experimental Medicine, Faculty of Health Sciences, Linkoping University, Linkoping, Sweden
    N Engl J Med 359:1909-20. 2008
    ..This trial assessed the ability of alum-formulated GAD (GAD-alum) to reverse recent-onset type 1 diabetes in patients 10 to 18 years of age...
  98. pmc Metal-activated C-peptide facilitates glucose clearance and the release of a nitric oxide stimulus via the GLUT1 transporter
    J A Meyer
    Department of Chemistry, Wayne State University, 5101 Cass Avenue, Detroit, MI 48202, USA
    Diabetologia 51:175-82. 2008
    ..We hypothesised that incubation of erythrocytes with C-peptide would improve the ability of these cells to release ATP, a stimulus for nitric oxide production...
  99. ncbi Islet transplants and impact on secondary diabetic complications: does C-Peptide protect the kidney?
    A M James Shapiro
    J Am Soc Nephrol 14:2214-6. 2003
  100. ncbi The effect of C-peptide on cognitive dysfunction and hippocampal apoptosis in type 1 diabetic rats
    Anders A F Sima
    Wayne State University School of Medicine, Department of Pathology, 540 E Canfield Ave, Detroit, MI 48201, USA
    Diabetes 54:1497-505. 2005
    ..Although these abnormalities were not fully prevented by C-peptide replacement, the findings suggest that this regime will substantially prevent cognitive decline in the type 1 diabetic population...
  101. ncbi C-peptide colocalizes with macrophages in early arteriosclerotic lesions of diabetic subjects and induces monocyte chemotaxis in vitro
    Nikolaus Marx
    Department of Internal Medicine II Cardiology, University of Ulm, Robert Koch Str 8, D 89081 Ulm, Germany
    Arterioscler Thromb Vasc Biol 24:540-5. 2004
    ..This study tested the hypothesis that C-peptide might participate in atherogenesis in these patients...

Research Grants66

  1. Role of Chromogranin A in Metabolic Syndrome
    Sushil K Mahata; Fiscal Year: 2013
    ..2. Evaluate the potential therapeutic effects of CST and its variants on insulin sensitivity and baroreflex sensitivity and heart rate variability in high fat diet-induced insulin resistant and in db/db diabetic mice. ..
  2. Comprehensive biomarker study to capitalize on existing GWAS in 10K South Asians
    Danish Saleheen; Fiscal Year: 2010
    ..We seek support for additional blood markers to PROMIS by assaying plasma biomarkers potentially relevant to atherogenesis, plaque rupture and/or thrombosis. ..
  3. PROSPECTIVE STUDIES OF DIET AND CANCER IN MEN AND WOMEN
    Walter C Willett; Fiscal Year: 2010
    ..The findings will contribute importantly to the prevention and prognosis of major cancers of men and women. ..
  4. Hyperglycemia and Pregnancy Outcome(HAPO)Follow Up Study
    Boyd E Metzger; Fiscal Year: 2013
    ....
  5. Role of the insulin/IGF-axis in incident CIN-2+
    Howard D Strickler; Fiscal Year: 2010
    ....
  6. Growth Factor and Antiapoptotic Gene Delivery to Human Islets
    Ram I Mahato; Fiscal Year: 2012
    ..This will decrease the number of islets required to achieve normoglycemia in type I diabetic patients. ..
  7. Immunology, Inflammation, and Endometriosis
    STACEY ANN MISSMER; Fiscal Year: 2012
    ..We believe that quantifying these factors may improve our understanding of the etiology and consequences of endometriosis. ..
  8. Dietary Patterns, Diet Quality + Cancer Risk
    Frank B Hu; Fiscal Year: 2012
    ..In addition, we will use a novel statistical approach, Reduced Rank Regression (RRR), to develop diet patterns that represent the effect of diet on cancer biomarkers. ..
  9. Genetics and Genomics of Maternal Glycemia During Pregnancy
    William L Lowe; Fiscal Year: 2013
    ....
  10. Mechanisms Underlying the Association between Maternal and Offspring Obesity
    PAULA CATHERINE CHANDLER-LANEY; Fiscal Year: 2013
    ....
  11. Targeting Inflammation in Type 2 Diabetes: Clinical Trial Using Salsalate
    Steven E Shoelson; Fiscal Year: 2010
    ....
  12. Prospective evaluation of IGF and IL-6 Dysregulation and Multiple Myeloma
    Graham A Colditz; Fiscal Year: 2010
    ..The team is led from by Drs. Colditz and Anderson and is supported by a senior statistician (Dr. Rosner) and a study director (Dr. Birmann) who is funded, in part, through a K award. ..
  13. Effect of Bariatric Surgery on Mechanisms of Type 2 Diabetes: The B2D Trial
    Philip R Schauer; Fiscal Year: 2013
    ..inform recruitment, retention, follow-up, and procedures for a longer-term trial that will compare surgery with advanced medical therapy, as we strive to identify the optimal treatment strategy to counter type 2 diabetes ..
  14. Measurement of Beta Cell Death in Diabetes
    Kevan C Herold; Fiscal Year: 2012
    ..The assay will have broad use for understanding [unreadable] death in diabetes and for developing new therapies to treat and prevent diabetes. ..
  15. Short Course G-CSF as Immunomodulatory Therapy for Type 1 Diabetes ? A Pilot Stud
    MICHAEL JAMES HALLER; Fiscal Year: 2010
    ..This protocol will explore the potential of the drug Granulocyte Colony Stimulation Factor (GCSF) to stimulate immune cells that can potentially change the immune system and protect insulin producing cells from further damage. ..
  16. PANCREAS AND ISLET TRANSPLANTATION IN HUMANS
    RODERICK PAUL ROBERTSON; Fiscal Year: 2013
    ..We envision the results will provide novel insights that will pertain not only to improving outcomes in TP/AIT recipients but also insights that will improve outcomes in alloislet transplantation for type 1 diabetic patients. ..
  17. Insulin Producing Cells from Amniotic Stem Cells for Diabetes Therapy
    Anthony Atala; Fiscal Year: 2009
    ..Successful development of an abundant source of transplantable insulin producing cells potentially would have a profound impact on the treatment of a major public health problem. ..
  18. Pancreas Volume in Preclinical Type 1 Diabetes
    Martha L Campbell-Thompson; Fiscal Year: 2013
    ..As well, monitoring pancreatic volume over time could function as an accurate, noninvasive, and simple surrogate marker for disease progression, allowing timely and guided clinical care. ..
  19. Natural History of Pre-diabetic Autoimmunity (DAISY)
    Marian J Rewers; Fiscal Year: 2013
    ..We will continue to make every effort to share DAISY resources with multiple investigators studying T1D and other autoimmune diseases, striving for an open-source database and repository. ..
  20. Endocrine pancreatic cell regeneration from bone marrow
    Mehboob A Hussain; Fiscal Year: 2010
    ..4) To identify the cell type within BM that contributes to the pancreatic endocrine cell population. The long-term goal of these studies is to evaluate transplantation of BM derived cells as a potential treatment for diabetes mellitus. ..
  21. ISLET CELL MEMBRANE ANTIBODIES IN DIABETES
    Christiane S Hampe; Fiscal Year: 2013
    ..Autoantigen-Fc fusion proteins of all four major autoantigens (insulin, GAD65, IA-2, and ZnT8) will be used in this approach. The results from this project will be crucial for the further development of a novel preventative therapy. ..
  22. Energy Balance, IGF Dysregulation and Multiple Myeloma
    Brenda M Birmann; Fiscal Year: 2010
    ..Thus, the proposed project represents an innovative research project strategically designed to enhance the career development of the Candidate. ..
  23. Standardization of C-Peptide and HbA1C (UC4)
    Randie Little; Fiscal Year: 2012
    ..Accurate, standardized measurement of C- peptide will aid in this goal and is also the subject of this application. ..
  24. A Humanized mouse model of B-islet cell autoimmunity
    Grete Sonderstrup; Fiscal Year: 2010
    ....
  25. Pediatric Type 1 diabetes: Intervention Trials With Glucagon Suppressors
    Rubina A Heptulla; Fiscal Year: 2010
    ..Uses of exenatide and/or pramlintide provide us with potentially new tools to improve glycemic control in children and adolescents with T1 DM and thus reduce associated long-term microvascular complications of this debilitating disease. ..
  26. AIRmax as sensitive measure of beta cell function in at-risk individuals
    Carla J Greenbaum; Fiscal Year: 2012
    ..Validation of surrogate metabolic biomarkers as described in this proposal will facilitate testing of novel therapies to prevent the disease. ..
  27. Maintaining Resistance Training in Older Prediabetic Adults: Theoretical Approach
    Richard A Winett; Fiscal Year: 2013
    ..abstract_text> ..
  28. Rational design of indole compounds as HIV fusion inhibitors
    Miriam Gochin; Fiscal Year: 2012
    ..Drugs in this class would be useful in microbicides to prevent infection, or could be given orally to treat infection as an alternative to the currently used fusion inhibitor Enfuvirtide(R), which must be given intravenously. ..
  29. Translatioanl studies of a bionic pancreas for out-patient diabetes management
    Steven J Russell; Fiscal Year: 2013
    ....
  30. Long Acting Native GLP-1 formulations for Type 1 Diabetes
    Elijah Bolotin; Fiscal Year: 2009
    ....
  31. Controlled expression of a cystatin C-peptide as therapy for Alzheimer's disease
    PHYLLIS ANN SHAW; Fiscal Year: 2012
    ....
  32. Analysis of beta cell death in Type 1 diabetes
    Kevan C Herold; Fiscal Year: 2013
    ..They may develop new treatment strategies based on an improved understanding of the kinetics and mechanisms of disease pathogenesis. ..
  33. Trainet: Diabetes Type 1 Prevention
    Peter A Gottlieb; Fiscal Year: 2013
    ..Our proposal for renewal outlines our past efforts, current approaches and future goals to not only maintain our current level of productivity, but to increase productivity over the next funding cycle. ..
  34. Aerobic Plus Resistance Training to Increase Insulin Sensitivity in African Ameri
    ROBERT LEE NEWTON; Fiscal Year: 2013
    ..Secondary outcomes are cardiovascular fitness, muscular strength, body weight and composition, and psychological outcomes. ..
  35. Markers of Beta Cell Dysfunction and Hypoglycemia in ACCORD
    Elizabeth R Seaquist; Fiscal Year: 2013
    ..0% at any visit prior to study completion or death and compare to values measured in matched ACCORD subjects in the intensive arm who achieved target glycemia on at least one occasion and completed the trial without severe hypoglycemia. ..
  36. Human Endocrine Cell Development
    James M Wells; Fiscal Year: 2013
    ..Our studies will unambiguously determine if NEUROG3 is required for the development of pancreatic versus intestinal endocrine cells and if it is not required, identify the molecular pathways that compensate for absence of NEUROG3. ..
  37. Oncogenic Signaling by DF3/MUC1 in Human Breast Cancer
    Donald W Kufe; Fiscal Year: 2013
    ..domain at the breast cancer cell surface;(2) To evaluate the development of orally bioavailable MUC1-C peptide inhibitors that block its function in the cytoplasm;(3) To define the activity of peptide and small molecule ..
  38. Glucose Counterregulation in Long Standing Type 1 Diabetes
    Michael R Rickels; Fiscal Year: 2013
    ....
  39. Development of an HIV-1 entry inhibitor pre-drug as a microbicide
    Min Lu; Fiscal Year: 2012
    ..1 ..
  40. Analysis of Pancreatic ??-cell Survival in Long-Lasting Type 1 Diabetes Patients
    IVAN VALDEZ; Fiscal Year: 2013
    ..Ultimately, the proposed experiments will provide a better understanding of the mechanisms that enhance ? -cell survival in the context of extreme-duration T1D. ..
  41. MECHANISMS OF HIV-1 MEMBRANE FUSION
    MICHAEL JEFFREY ROOT; Fiscal Year: 2013
    ..The research will ultimately facilitate therapeutic and vaccine development for the treatment and prevention of AIDS. ..
  42. Prediction and Prevention of Type 1 Diabetes - TrialNet
    Dorothy J Becker; Fiscal Year: 2013
    ..The strength of this proposal is the expertise and experience of the investigators,well established collaborations across centers and a novel intervention strategy ..
  43. TrialNet: University of Florida Clinical Center and Network
    DESMOND ARTHUR SCHATZ; Fiscal Year: 2013
    ....
  44. Type 1 Diabetes-A Proposal for Prevention &Intervention
    ANTOINETTE M MORAN; Fiscal Year: 2013
    ..The long-term goal is to gather preliminary data in anticipation of an intervention trial of peripheral-blood derived autologous CD4+/CD25+/FoxP3+ treatment of new onset T1D. ..
  45. NANO-CHIP HIV DETECTION IN VULNERABLE POPULATIONS
    Glen N Gaulton; Fiscal Year: 2011
    ....
  46. A memory CD4 T-cell biomarker predicts T1D progression and treatment response
    Mark Peakman; Fiscal Year: 2013
    ....
  47. Type 1 Diabetes TrialNet: Toronto Clinical Centre
    DIANE K WHERRETT; Fiscal Year: 2013
    ..Preserved endogenous insulin secretion has been found to be associated with reduced of rates of the diabetes complications of hypoglycemia, nephropathy and retinopathy. ..
  48. Type 1 Diabetes TrialNet: Clinical Center at Yale University (U01)
    Kevan C Herold; Fiscal Year: 2013
    ..These sites are in the New York region, the midwest, and Texas. We therefore anticipate that our ability to recruit for future TrialNet studies will increase by several orders of magnitude. ..
  49. Type 1 Diabetes TrialNet Clinical Center: Effects of Alefacept in New Onset T1D
    Jennifer B Marks; Fiscal Year: 2013
    ..The primary immunological outcome will be a 50-60% reduction in the frequency of memory T cells during the treatment phases. ..
  50. Development of new anti-inflammatory peptides for treatment of type I diabetes
    Soren Mogelsvang; Fiscal Year: 2013
    ....
  51. Gene-engineered dendritic cell therapy for diabetics
    Massimo Trucco; Fiscal Year: 2003
    ..The ultimate result could include less intensive or even a complete cessation of insulin replacement therapy in newly-diagnosed diabetics as well as, perhaps, a means of preventing diabetes. ..
  52. Gene-engineered dendritic cell therapy for diabetics
    Massimo Trucco; Fiscal Year: 2006
    ..The ultimate result could include less intensive or even a complete cessation of insulin replacement therapy in newly-diagnosed diabetics as well as, perhaps, a means of preventing diabetes. ..
  53. Biodemographic Tools for Investigating Postpartum Amenorrhea
    DARRYL HOLMAN; Fiscal Year: 2009
    ..The resulting endocrine tools will also be useful for other large-scale (field) studies that require measurement of relative metabolic load. ..
  54. CHRONIC PSYCHOSOCIAL STRESS, METABOLIC SYNDROME, AND CHD
    Peter Vitaliano; Fiscal Year: 2001
    ..This research should elucidate psychophysiological mediators of chronic stress and CHD and, therefore, have clinical implications. ..
  55. NUTRITIONAL AND BIOCHEMICAL/GENETIC MARKERS OF CANCER
    Jing Ma; Fiscal Year: 2007
    ..Hence, the proposed project is highly cost-efficient. ..
  56. Ginkgo Biloba Extract & The Insulin Resistance Syndrome
    George Kudolo; Fiscal Year: 2004
    ..The results of this study should also provide valuable information for designing new therapeutic strategies for the treatment of diseases in the insulin resistance syndrome. ..
  57. GENETICS OF THE METABOLIC SYNDROME IN JAPANESE AMERICANS
    Melissa Austin; Fiscal Year: 2002
    ....
  58. IMMUNE MECHANISMS IN HUMAN DIABETES
    MERL CHARLES; Fiscal Year: 1990
    ..The results of this study could change the direction of current thoughts and practices regarding remission induction and the treatment of new onset type 1 diabetes...
  59. STABLE ISOTOPE LABELED PROTEINS AND DRUG DISPOSITION
    Fred Abramson; Fiscal Year: 2002
    ..Overall, this work will show he capabilities of a new strategy by which a more accurate understanding of the fundamental pharmacology of an increasingly important class of drugs can be gained. ..
  60. Commercial Feasibility Assessment of Pancreatic Islet Progenitor Cell Technology
    Kelvin Brockbank; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  61. PANCREATIC PRESERVATION FOR CLINICAL TRANSPLANTATION
    FOLKERT BELZER; Fiscal Year: 1991
    ..The solutions developed will be tested in clinical pancreas preservation and transplantation...
  62. Preservation of Beta Cells by Glutamate Decarboxylase
    Diane Wherrett; Fiscal Year: 2007
    ..The primary analysis will test the difference in proportion of subjects and controls with FPIR below 1st percentile for age, using a two-sided Chi Square test with continuity correction. ..
  63. Biomarkers for protection against complicatios and beta-cell destruction
    George King; Fiscal Year: 2009
    ..Thus, we are proposing three studies to identify potential protective factors that can correlate to the absence of complications and the presence of islet beta cell function in this group of type 1 diabetic patients. ..
  64. DIABETES IN THE 15-34 YEAR OLD
    Ake Lernmark; Fiscal Year: 1999
    ..The investigators state that these studies will help to define pathogenetic mechanisms of IDDM to produce insights to the possibility of prevention or cure of this disease. ..
  65. Cord Blood Immunoregulation of Type 1 Diabetes
    Mark Atkinson; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable] [unreadable]..
  66. HIGH GLYCEMIC DIET AND RISK OF NIDDM AND CHD
    Simin Liu; Fiscal Year: 2002
    ..Through the process, Dr. Liu will acquire ample skills and experience to become an independent clinician scientist and educator in the field of nutrition and chronic disease prevention and control. ..